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Optical coherence tomography (OCT) is a rapid noncontact method that allows in vivo imaging of the retina and it has become an
important component in clinical practice. OCT is a useful ancillary tool for assessing retinal diseases because of its ability to provide
cross-sectional retinal images and quantitatively analyze retinal morphology. The introduction of spectral-domain OCT provided
major improvements in image acquisition speed and image resolution. Future studies will address how these major technologic
advances will impact the use of OCT in research and clinical practice.
1. Introduction
Optical coherence tomography (OCT)was introduced in 1991
as a noninvasive in vivo ophthalmic imaging technique for
facilitating retinal thickness measurement [1, 2]. This high-
resolution, cross-sectional imaging technique allows detailed
assessment of retinal thickness and morphologic evaluation
of the neurosensory retinal layers, retinal pigment epithelium
(RPE), and choroid (Figure 1).
OCT is an interferometric imaging technique that gen-
erates cross-sectional images by mapping the depth-wise
reflections of low-coherence laser light fromdifferent kinds of
tissue. Spectral-domain OCT (SD-OCT) or Fourier-domain
OCT refers to Fourier transformation of the optical spectrum
of the low-coherence interferometer. The optical spectrum
output of an interferometer exhibits peaks and troughs, and
the period of such modulation is proportional to the optical
path differences in the interferometer. Imaging of multilayer
objects, such as the retina, results in various modulation
periodicities representing the depth of each layer. SD-OCT
identifies the retinal thickness from the RPE to the inner
limiting membrane [3].
The most important advantage of SD-OCT compared
with conventional time-domain OCT (TD-OCT) technique
is the increased scanning speed [2, 4, 5]. With SD-OCT
imaging, acquisition of 25,000 to 100,000 scans/second is
routinely possible [5]. This is more than 100 times faster
than the TD technique. The axial image resolution of OCT
depends on the bandwidth of the low-coherence light source.
Most OCT systems use superluminescent diodes with a
bandwidth of about 20 to 50 nanometers (nm) that allows
axial resolution of 5 to 10microns. Commercial OCT systems
use light sources between 800 and 900 nm wavelengths,
allowing for good retinal imaging. SD-OCT has improved
visualization of the intraretinal morphologic features, which
facilitates evaluation of the integrity of each retinal layer.
The image quality of all SD-OCT instruments is sufficient to
delineate as many as 10 retinal layers [4]. Another important
advantage of SD-OCT instrumentation is the possibility to
obtain three-dimensional scans allowing for visualization of
structural changes in the vitreoretinal interface and the retina
in large areas [4].
This report is an evidence-based review of the increasing
role of OCT in the diagnosis and management of ocular
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Figure 1: A spectral domain optical coherence tomography line scan
of a normal eye.
disorders, particularly in age-related macular degeneration
(AMD), diabetic macular edema (DME), and retinal vein
occlusion (RVO).
2. Macular Edema
Macular edema, whether associated with diabetic retinopa-
thy, uveitis, retinal vascular diseases (branch and central reti-
nal vein occlusions (BRVO/CRVO)), or postcataract (Irvine-
Gass) macular edema, or in idiopathic cases, can lead to
severe visual loss if undetected and untreated. Current
diagnostic techniques for assessingmacular edema, including
biomicroscopy, fundus photography, and fluorescein angiog-
raphy (FA), are widely used, but interpretation of the results
can be subjective, and subtle changes in retinal thickness in
early stage macular edema may not be evident using these
techniques.
OCT is considered the best reference standard for detect-
ing and quantifying macular edema compared to ultra-
sound, retinal thickness analysis, and scanning laser ophthal-
moscopy [6, 7]. Compared to biomicroscopy and FA, OCT
has superior sensitivity and greater resolution for detecting
macular edema and subretinal fluid [8–10].
Cystoid macular edema (Figure 2) can be seen clearly on
OCT scans as multiple circular cystic spaces in the retina,
indicating intraretinal edema.The cystic spaces are round and
originate around the outer plexiform layer but can progress to
involve the photoreceptor layer and the inner retinal layers.
Occasionally, cystic retinal edema can enlarge CRT and have
the appearance of a foveal pseudocyst.
2.1. OCT in DiabeticMacular Edema. DME is themost com-
mon cause of moderate visual loss in patients with diabetes
[11]. In 1998, Hee et al. were the first to use OCT to measure
the retinal thickness in patients with DME [12]. As a result,
OCT imaging has rapidly been integrated into diagnosis
and management of DME in routine clinical practice and
clinical trials [3]. OCT was found to be highly sensitive and
specific for detecting DME compared to other diagnostic
modalities such as FA and the Retinal Thickness Analyzer
(Talia Technology Ltd., Neve-Ilan, Israel) [7, 13].
The prevalence of DME increases from 0% to 3% in
individuals with recent diagnoses of diabetes to 28% to 29%
in those with diabetes for longer than 20 years [14], making
it the principal mechanism of visual loss in patients with
nonproliferative diabetic retinopathy [15]. The pathogenesis
is not understood completely, but intraretinal fluid develops
Figure 2: Cystoid macular edema can be seen clearly on OCT scans
asmultiple circular cystic spaces in the retina, indicating intraretinal
edema (white arrowhead).The cystic spaces are round and originate
around the outer plexiform layer.
Figure 3: An OCT horizontal line scan of a 62-year-old man with
diabetic retinopathy and macular edema-intraretinal cysts (white
arrowhead).
secondary to microaneurysm formation, increased vascular
permeability, and breakdown of the blood-retinal barrier
[5, 16] (Figure 3). Vascular endothelial growth factor (VEGF)
may play an important role [17]. The ability to detect and
quantify the central retinal thickness in patients with clin-
ically diagnosed DME is important when treating patients
with diabetes. Other causes of limited visual function include
macular ischemia [18], photoreceptor dysfunction [19], and
accumulated subfoveal hard exudates [20].
DME had been characterized as focal or diffuse based
on clinical examination and FA findings [11]. OCT allows
for more precise evaluation of the retinal pathology in
DME, including the retinal thickness and edema, vitreo-
macular interface abnormalities, subretinal fluid, and foveal
microstructural changes. Additional advantages include the
possibility of correlations with FA and the ability to quan-
titatively monitor responses to treatment of DME by laser,
intravitreal pharmacotherapies, and vitreoretinal surgery [5].
The test-retest variability of OCT measurements for retinal
thickness is less than 10% in patients with diabetes both
with and without DME [21, 22]. Therefore, a change in
OCT thickness exceeding 10% is often considered clinically
relevant, and the change in relative central subfield thickening
is minimal, with a mean decrease of only 6% between 8 a.m.
and 4 p.m. [23]. Before OCT technology, precise monitoring
of the CRT was impossible.
The OCT findings were well correlated with other eval-
uation techniques for DME. Although there is a moderate
correlation between the retinal thickness measured by OCT
and visual acuity (VA), OCT cannot replace the VA because
there is a high degree of variability [3]. Macular edema and
thickness are only two factors amongmany that affect the VA
in patients with DME. Macular ischemia and foveal exudates
(Figure 4) also contribute to the poor prognosis. Recently, log
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Figure 4: An OCT horizontal line scan of a woman with diabetes,
with a juxtafoveal accumulation of hard exudates (white arrowhead)
and substantial fluid at the level of outer plexiform layer (yellow
arrowhead). Diffuse hyperreflective hard exsudates can also be seen
(red arrowhead).
changes in OCT have been proposed as a better method of
analyzing OCT parameters instead of using absolute values,
since the same degree of absolute changes in microns may
be qualitatively different depending on the baseline retinal
thickness [24].
To investigate the relationship between VA and the CRT
measured by OCT, 251 eyes of 210 patients with DME were
enrolled in a cross-sectional and longitudinal randomized
clinical trial [25].TheDiabetic Retinopathy Clinical Research
Network documented amodest correlation between the best-
corrected VA and the CRT measured by OCT before focal
laser photocoagulation and a modest correlation between
changes in VA and changes in thickening of the center point
measured by OCT during the first year after laser treatment.
Many eyes with a thickened macula had excellent VA and
many eyes with a macula of normal thickness had decreased
VA.The results suggested that OCTmeasurements, although
an important clinical tool, are not an ideal surrogate for VA
as a primary outcome in studies of DME.
OCT also allows analysis of the integrity of the outer
retinal layers in DME. Various studies have reported that the
integrity of the outer retinal layer is linked directly to the
visual prognosis [26–29]. Disruption of the hyperreflective
photoreceptor inner segment/outer segment junction on
OCT, located just above the RPE, may reveal damage to the
macular photoreceptors [5].
Many treatment options exist for treating DME, such as
focal therapies laser [11], pharmacotherapies, and systemic
adjuvant therapies to control glucose levels [30, 31] and blood
pressure [32, 33].
In 1985, the Early Treatment Diabetic Retinopathy Study
(ETDRS) defined clinically relevant macular edema. The
study further reported that focal or grid photocoagulation of
eyes with clinically relevant macular edema reduced the 3-
year risk of losing three or more lines of VA by 50%, from
30% in the control group to 15% in the laser group [11].
Treating DME with peribulbar triamcinolone acetonide
did not significantly improve the central subfield macular
thickness measured by OCT or VA [34]. Intravitreal tri-
amcinolone had short-term benefits; however, when triam-
cinolone was compared with laser in a randomized trial,
steroids were inferior at 2 years, with substantially higher
rates of complications, surgical interventions, and a three-line
visual loss [35].
Figure 5: A line scan of an eye with macular edema secondary to
an active exudative AMD. The technique allows for visualization of
the cystic spaces (white arrowhead) and other changes in the retinal
layers. Note the hyperreflective layer underneath the neurosensory
retina suggestive of the neovascular membrane complex (yellow
arrowhead).
The newest frontier in treating DME involves the use
of anti-VEGF agents. Ranibizumab (Lucentis, Genentech,
Inc., South San Francisco, CA), a monoclonal antibody
fragment with binding affinity for VEGF-A, has been evalu-
ated for treating DME [36]. Pilot studies found that intrav-
itreal ranibizumab reduced macular edema on SD-OCT
and improved VA in patients with DME [17]. Ranibizumab
received Food andDrugAdministration approval for treating
DME based on the results of major clinical trials [37].
The benefits of ranibizumab for improving the VA and
central foveal thickness on SD-OCT can be observed as
early as 7 days after treatment initiation; however, whether
and for how long the beneficial effects of ranibizumab on
retinopathy severity and progression persist after therapy ces-
sation also need to be determined [37]. Diabetic Retinopathy
Clinical Research Network is also evaluating this question
[38].
2.2. OCT in Age-Related Macular Degeneration. SD-OCT
is becoming an integral component in the diagnosis and
management of AMD. OCT testing provides qualitative and
quantitative assessment of various AMD presentations and
detects early nonexudativeAMDchanges, such as drusen and
RPE atrophy, and exudative AMD findings, such as intrareti-
nal fluid, RPE detachment, retinal angiomatous proliferation,
and choroidal neovascular membranes (Figure 5). OCT may
be used tomeasure changes in drusen volume and tomeasure
geographic atrophy incensement [39]. RPE tears are not
infrequent among eyes treated with intravitreal anti-VEGFs,
and the presence, increased height, and shorter duration
of PED are potential risk factors for RPE tears associated
with anti-VEGF therapy. OCT gives us an important tool in
detecting and measuring both PED increase and RPE tears
[40].
The ability to detect intraretinal fluid on OCT images
is an effective way to guide treatment and retreatment,
because intraretinal fluid is associated with active neovas-
cular membranes. OCT imaging features that may be asso-
ciated with choroidal neovascularization include thickening
or fragmentation of the RPE, choriocapillaris, intraretinal
and subretinal fluid accumulation related to neovascular-
ization exudation, and pigment epithelial detachment [41]
(Figure 6). Serial SD-OCT scanning is essential to monitor
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Figure 6: An OCT line scan of a 73-year-old man with exudative
AMD. The white arrowhead shows that the hyporeflective space
below the neurosensory retina is clearly visible, suggesting the
presence of fluid. Yellow arrowhead represents a hemorrhagic
detachment of the retinal pigment epithelium (PED) and vitreomac-
ular traction in addition to vitreous alterations (red arrowhead).
the responses to anti-VEGF therapies, which decrease the
activity of the neovascular membranes, with a resultant
reduction in intraretinal edema and improved retinal archi-
tecture.
2.3. OCT in Retinal Vein Occlusion. RVO is a common, sight-
threatening retinal vascular disorder and the second most
common retinal vascular disease after diabetic retinopathy.
The clinical characteristics, prognosis, and response to treat-
ment are affected by the location of the occlusion in the
retinal venous vasculature, the presence of macular edema,
and the extent of the retinal nonperfusion. The location
of the occlusion may affect the severity of the clinical
manifestations.
Macular edema, a major cause of visual loss in patients
with RVO [42], involves a spectrum of different pathologic
retinal changes, including intraretinal fluid accumulation
with diffuse retinal thickening or formation of cystoid spaces,
subretinal fluid accumulation, or macular traction due to
epiretinal membrane formation (Figure 7). SD-OCT assess-
ment of the VA and measurement of retinal thickness and
structural changes provides useful information for determin-
ing treatment strategy for RVO.
Some parameters seen on SD-OCT seem to be correlated
negatively with visual recovery after RVO, such as foveal
thickness, serous retinal detachment, central cystoid spaces,
and pigment epithelial changes. When a very thick fovea
(more than 700 microns) is seen on SD-OCT, an ischemic
form of CRVO should be suspected [43]. Loss of the foveal
photoreceptor junction line and absence of the inner retinal
layers on late-stage SD-OCT images are correlated with poor
visual outcomes in patients with CRVO [44] and BRVO
[45–47]. In addition, loss of the inner retinal layers on
late-stage SD-OCT images is correlated significantly with
macular ischemia diagnosed in early FA studies [48]. These
specific structural changes suggest that SD-OCT can be an
important tool for evaluating and managing macular edema
and predicting the long-term visual prognosis in patients
with CRVO. The relationship between the CRT and VA has
not been well established in CRVO [48].
The current management of macular edema secondary to
CRVO relies on two different approaches involving intrav-
itreal therapy: anti-VEGF therapy [49, 50] or steroids [51].
Figure 7: Macular edema in a 75-year-old woman with CRVO.
There are several cystic spaces in the retinal layers (white arrow-
head), although the foveal depression is preserved (yellow arrow-
head).
Management of BRVO includes grid laser photocoagulation,
steroids, or anti-VEGF agents.
3. Conclusion
SD-OCT technology has revolutionized the evaluation and
treatment of macular edema. The technology facilitates
quantitative assessment of the degree of retinal thickness,
which has proved to be useful in the diagnosis, management,
and follow-up of patients with macular edema, including
assessment of foveal microstructural changes. OCT is a
highly accurate and reproducible method for diagnosing
macular edema that compares well to the standard clinical
examination, ETDRS photos, and FA. Although it is useful
for anatomic study, OCT is not an effective surrogate for
functional tests such as VA measurement in the assessment
of macular edema [3]. Future research in SD-OCT imaging
likely will result in improvements in resolution, speed, image
registration, three-dimensional imaging, and the ability to
combine SD-OCT with other various diagnostic modalities
that will further our ability to evaluate macular edema in
clinical practice and trials for our patients with diabetes,
RVO, and exudative AMD.Many therapeuticmodalities exist
for treating those conditions, with some believed to be an
exciting new frontier.
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